



FEP Medical Policy Manual

FEP 2.02.31 Myocardial Strain Imaging

Annual Effective Policy Date: April 1, 2026

Original Policy Date: July 2019

Related Policies:

None

Myocardial Strain Imaging

Description

Description

Myocardial strain refers to the deformation (shortening, lengthening, or thickening) of the myocardium through the cardiac cycle. Myocardial strain can be measured by tissue Doppler imaging or, more recently, speckle-tracking echocardiography. Speckle-tracking echocardiography uses imaging software to assess the movement of specific markers in the myocardium that are detected in standard echocardiograms. It is proposed that a reduction in myocardial strain may indicate sub-clinical impairment of the heart and can be used to inform treatment before the development of symptoms and irreversible myocardial dysfunction.

OBJECTIVE

The objective of this evidence review is to evaluate whether myocardial strain imaging improves the net health outcome in individuals exposed to medications or radiation that could result in cardiotoxicity.

POLICY STATEMENT

Myocardial strain imaging in individuals who have exposure to medications or radiation that could result in cardiotoxicity is **investigational**.

Myocardial strain imaging is **investigational** in all other situations.

POLICY GUIDELINES

None

BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

FDA REGULATORY STATUS

A number of image analysis systems have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. Examples of these are shown in Table 1. For example, the Echolnsight software system (Epsilon Imaging) "enables the production and visualization of 2-dimensional tissue motion measurements (including tissue velocities, strains, strain rates) and cardiac structural measurement information derived from tracking speckle in tissue regions visualized in any B mode (including harmonic) imagery loops as captured by most commercial ultrasound systems" (K110447). The FDA determined that this device was substantially equivalent to existing devices (eg, syngo US Workplace, Siemens, K091286) for analysis of ultrasound imaging of the human heart.

Table 1. Examples of Software That Have Received FDA Clearance

Brand Name	Manufacturer	510(k) Number	FDA Product Code	Clearance Date
Myostrain	Myocardial Solutions	K182756	LNH	02/14/2019
Vivid	GE	K181685	IYN	10/25/2018
Aplio	Toshiba	K173090	IYN	01/11/2018
2D CARDIAC PERFORMANCE ANALYSIS	Tomtec	K120135	LLZ	04/13/2012
Echolnsight	Epsilon Imaging	K110447	LLZ	05/27/2011
Q-lab	Phillips	K023877	LLZ	12/23/2002

FDA: Food and Drug Administration.

RATIONALE

Summary of Evidence

For individuals who have exposure to medications or radiation that could result in cardiotoxicity who receive myocardial strain imaging, the evidence includes systematic reviews of observational studies and a randomized controlled trial (RCT). Relevant outcomes include symptoms, morbid events, quality of life, treatment-related mortality, and treatment-related morbidity. A systematic review of 13 studies with 384 patients treated for cancer suggests that myocardial strain imaging with tissue Doppler imaging or speckle-tracking echocardiography may be able to identify changes in myocardial deformation that precede changes in left ventricle ejection fraction. Two recently published observational studies reported conflicting evidence at 6 months post-radiotherapy on whether longitudinal strain reduction was associated with radiotherapy dose. Although myocardial strain imaging may detect sub-clinical myocardial changes, the value of these changes in predicting clinical outcomes or guiding therapy is uncertain. In the Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes (SUCCOUR) RCT, left ventricle surveillance with global longitudinal strain was associated with an increased use of cardioprotective therapy and a lower incidence of cancer-therapy-related cardiac dysfunction as compared to left ventricular ejection fraction surveillance. However, no difference in the primary endpoint of final left ventricular ejection fraction at 1-year follow-up was observed between the groups and interpretation of findings was limited by important design and relevance limitations. At 3-year follow-up, despite the increase in the use of cardioprotective therapies in the global longitudinal strain-guided group, there were minimal differences in

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

the change in left ventricular ejection fraction between groups. Additional studies are indicated to better define the threshold for cardioprotective therapy and assess whether a global longitudinal strain-guided approach to cardioprotective therapy reduces the long-term risk of heart failure and improves clinical outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American College of Cardiology et al

In 2019, the American College of Cardiology, American Association for Thoracic Surgery, American Heart Association (AHA), American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and the Society of Thoracic Surgeons published appropriate use criteria for multimodality imaging in the assessment of cardiac structure and function in nonvalvular heart disease (Table 2).²

Using a modified Delphi approach, the panel rated indications as "appropriate", "may be appropriate", and "not appropriate".¹³ The specific studies that formed the basis of the American College of Cardiology guidelines are not cited; however, they note that they used American College of Cardiology/American Heart Association clinical practice guidelines whenever possible.

Of 81 indications considered for strain rate imaging, the panel rated only 4 as "appropriate" (Table 2). Three of the 4 concerned evaluation (initial or follow-up) in patients prior to and following exposure to potentially cardiotoxic agents. The other indication was follow-up testing to clarify initial diagnostic testing for patients with suspected hypertrophic cardiomyopathy. The guidelines did not separate out imaging with speckle tracking and tissue Doppler and did not make recommendations related to the comparative effectiveness of these imaging modalities.

The panel rated 14 other indications "may be appropriate" (Table 2). According to the panel, interventions in this category should be performed depending on individual clinical patient circumstances and patient and provider preferences, including shared decision making.¹³

Table 2. Summary of American College of Cardiology Appropriate Use Criteria for Myocardial Strain Imaging

Clinical Scenario and Indication	Rating
<i>Initial evaluation in an asymptomatic patient:</i>	
- Initial evaluation prior to exposure to medications/radiation that could result in cardiotoxicity/heart failure	Appropriate
- Initial cardiac evaluation of a known systemic, congenital, or acquired disease that could be associated with structural heart disease	May be appropriate
- Screening evaluation for structure and function in first-degree relatives of a patient with an inherited cardiomyopathy	May be appropriate
- Preparticipation assessment of an asymptomatic athlete with 1 or more of the following: abnormal examination, abnormal ECG, or definite (or high suspicion for) family history of inheritable heart disease)	May be appropriate
<i>Initial evaluation of a patient with clinical signs and/or symptoms of heart disease:</i>	
- Initial evaluation when symptoms or signs suggest heart disease	May be appropriate

- Arrhythmias or conduction disorders: Newly diagnosed LBBB; Nonsustained VT	May be appropriate
- Palpitations/presyncope/syncope: Clinical symptoms or signs consistent with a cardiac diagnosis known to cause presyncope/syncope (including but not limited to hypertrophic cardiomyopathy and heart failure)	May be appropriate
- Respiratory failure/exertional shortness of breath: Exertional shortness of breath/dyspnea or hypoxemia of uncertain etiology	May be appropriate
- HF/cardiomyopathy: Initial evaluation of known or suspected HF (systolic or diastolic) based on symptoms, signs, or abnormal test results to assess systolic or diastolic function and to assess for possible etiology (CAD, valvular disease); Suspected inherited or acquired cardiomyopathy (eg, restrictive, infiltrative, dilated, hypertrophic)	May be appropriate
- Device therapy: Known implanted pacing/ICD/CRT device with symptoms possibly due to suboptimal device settings	May be appropriate
- Cardiac transplantation: Monitoring for rejection or coronary arteriopathy in a cardiac transplant recipient	May be appropriate
- Other: Suspected pericardial diseases	May be appropriate
<i>Sequential or follow-up testing to clarify initial diagnostic testing:</i>	
- Evaluation of suspected hypertrophic cardiomyopathy	Appropriate
- Re-evaluation (1 y) in a patient previously or currently undergoing therapy with potentially cardiotoxic agents	Appropriate
- Periodic reevaluation in a patient undergoing therapy with cardiotoxic agents and worsening symptoms	Appropriate
- Pulmonary hypertension in the absence of severe valvular disease	May be appropriate
- Comprehensive further evaluation of undefined cardiomyopathy	May be appropriate
- Evaluation of suspected cardiac amyloidosis	May be appropriate
<i>Sequential or follow-up testing: new or worsening symptoms or to guide therapy</i>	
Re-evaluation of known structural heart disease with change in clinical status or cardiac examination or to guide therapy	May be appropriate
Re-evaluation of known cardiomyopathy with a change in clinical status or cardiac examination or to guide therapy	May be appropriate
Re-evaluation of known HF (systolic or diastolic) with a change in clinical status or cardiac examination without a clear precipitating change in medication or diet	May be appropriate
Re-evaluation for CRT device optimization in a patient with worsening HF	May be appropriate

CAD: coronary artery disease; CRT: cardiac resynchronization therapy; ECG: electrocardiogram; HF: heart failure; ICD: implantable cardioverter-defibrillator; LBBB: left bundle branch block; VT: ventricular tachycardia.

Source: Adapted from Doherty et al (2019).²

American Heart Association

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

A 2023 scientific statement from the AHA regarding cancer treatment-associated cardiovascular toxicity included some discussion of global longitudinal strain.¹⁴ The authors acknowledged that some definitions of cancer therapy-related cardiac dysfunction (CTRCD) rely on the use of changes in strain; however, there are no specific recommendations regarding appropriate use of global longitudinal strain in the statement.

American Society of Clinical Oncology

In 2017, the American Society of Clinical Oncology noted that measurement of strain has been demonstrated to have some diagnostic and prognostic use in patients with cancer receiving cardiotoxic therapies but that there have been no studies demonstrating that early intervention based on changes in strain alone can result in changes in risk and improved outcomes.¹⁵ The American Society of Clinical Oncology also notes that screening for asymptomatic cardiac dysfunction using advanced imaging could lead to added distress in cancer survivors.

International Cardio-Oncology Society

A 2021 consensus statement from the International Cardio-Oncology Society included global longitudinal strain in the definitions of mild and moderate asymptomatic CTRCD.¹⁶ Mild CTRCD was defined as an LVEF of at least 50% AND a new relative decline in global longitudinal strain by more than 15% from baseline AND/OR new rise in cardiac biomarker. Moderate CTRCD was defined as new LVEF reduction by at least 10% to an LVEF of 40% to 49% OR new LVEF reduction by less than 10% to an LVEF of 40% to 49% AND new relative decline in global longitudinal strain by more than 15% from baseline AND/OR new rise in cardiac biomarker.

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

REFERENCES

1. Smiseth OA, Torp H, Opdahl A, et al. Myocardial strain imaging: how useful is it in clinical decision making?. *Eur Heart J*. Apr 14 2016; 37(15): 1196-207. PMID 26508168
2. Doherty JU, Kort S, Mehran R, et al. ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2019 Appropriate Use Criteria for Multimodality Imaging in the Assessment of Cardiac Structure and Function in Nonvalvular Heart Disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and the Society of Thoracic Surgeons. *J Am Soc Echocardiogr*. May 2019; 32(5): 553-579. PMID 30744922
3. Trivedi SJ, Altman M, Stanton T, et al. Echocardiographic Strain in Clinical Practice. *Heart Lung Circ*. Sep 2019; 28(9): 1320-1330. PMID 31064715
4. Yingchoncharoen T, Agarwal S, Popović ZB, et al. Normal ranges of left ventricular strain: a meta-analysis. *J Am Soc Echocardiogr*. Feb 2013; 26(2): 185-91. PMID 23218891
5. Thavendiranathan P, Poulin F, Lim KD, et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. *J Am Coll Cardiol*. Jul 01 2014; 63(25 Pt A): 2751-68. PMID 24703918
6. Jacob S, Pathak A, Franck D, et al. Early detection and prediction of cardiotoxicity after radiation therapy for breast cancer: the BACCARAT prospective cohort study. *Radiat Oncol*. Apr 07 2016; 11: 54. PMID 27056179
7. Walker V, Lairez O, Fondard O, et al. Early detection of subclinical left ventricular dysfunction after breast cancer radiation therapy using speckle-tracking echocardiography: association between cardiac exposure and longitudinal strain reduction (BACCARAT study). *Radiat Oncol*. Nov 14 2019; 14(1): 204. PMID 31727075
8. Honaryar MK, Locquet M, Allodji R, et al. Cancer therapy-related cardiac dysfunction after radiation therapy for breast cancer: results from the BACCARAT cohort study. *Cardiooncology*. Aug 26 2024; 10(1): 54. PMID 39187877
9. Walker V, Crijns A, Langendijk J, et al. Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer: Protocol for a European Multicenter Prospective Cohort Study (MEDIRAD EARLY HEART Study). *JMIR Res Protoc*. Oct 01 2018; 7(10): e178. PMID 30274965

10. Locquet M, Spoor D, Crijns A, et al. Subclinical Left Ventricular Dysfunction Detected by Speckle-Tracking Echocardiography in Breast Cancer Patients Treated With Radiation Therapy: A Six-Month Follow-Up Analysis (MEDIRAD EARLY-HEART study). *Front Oncol.* 2022; 12: 883679. PMID 35837099
11. Thavendiranathan P, Negishi T, Somerset E, et al. Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy. *J Am Coll Cardiol.* Feb 02 2021; 77(4): 392-401. PMID 33220426
12. Negishi T, Thavendiranathan P, Penicka M, et al. Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 3-Year Results of the SUCCOUR Trial. *JACC Cardiovasc Imaging.* Mar 2023; 16(3): 269-278. PMID 36435732
13. Hendel RC, Lindsay BD, Allen JM, et al. ACC Appropriate Use Criteria Methodology: 2018 Update: A Report of the American College of Cardiology Appropriate Use Criteria Task Force. *J Am Coll Cardiol.* Feb 27 2018; 71(8): 935-948. PMID 29471942
14. Addison D, Neilan TG, Barac A, et al. Cardiovascular Imaging in Contemporary Cardio-Oncology: A Scientific Statement From the American Heart Association. *Circulation.* Oct 17 2023; 148(16): 1271-1286. PMID 37732422
15. Armenian SH, Lacchetti C, Lenihan D. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary. *J Oncol Pract.* Apr 2017; 13(4): 270-275. PMID 27922796
16. Herrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. *Eur Heart J.* Jan 31 2022; 43(4): 280-299. PMID 34904661

POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

Date	Action	Description
June 2019	New policy	Policy created with literature review through January 12, 2019. Considered investigational.
June 2020	Replace policy	Policy updated with literature review through January 22, 2020; reference added. Investigational policy statement added to address cardiotoxicity.
June 2021	Replace policy	Policy updated with literature review through March 18, 2021. No references added. Policy statements unchanged.
September 2022	Replace policy	Policy updated with literature review through March 14, 2022; reference added. Policy statements unchanged.
September 2023	Replace policy	Policy updated with literature review through March 7, 2023; reference added. Policy statements unchanged.
September 2024	Replace policy	Policy updated with literature review through March 15, 2024; references added. Policy statement unchanged.
September 2024	Replace policy	Policy updated with literature review through March 15, 2024; references added. Policy statement unchanged.
September 2025	Replace policy	Policy updated with literature review through March 15, 2025; references added. Policy statement unchanged.
March 2026	Replace policy	Policy updated with literature review through March 15, 2025; references added. Policy statement unchanged.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.